Physician profile
Robert Walter Jensen
NPI 1083741961
$8,041.62
in general payments reported to CMS, 2019-2025
53 companies · $81.13 in 2025
The $81.13 reported for 2025 was less than what a typical Neuro-Ophthalmology provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2021: $1,103 · 2022: $2,054 · 2023: $2,901 · 2024: $1,278 · 2025: $81.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,260.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $617.08 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $540.68 | 2019-2024 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $534.36 | 2019-2024 | |
| Ucb, INC. | $530.16 | 2019-2024 | Briviact, Rystiggo |
| Jazz Pharmaceuticals INC. | $448.33 | 2022-2024 | |
| Genzyme Corporation | $446.56 | 2019-2024 | |
| Lilly USA, LLC | $397.23 | 2021-2024 | Amyvid, Emgality, Reyvow |
| Genentech USA, INC. | $356.47 | 2019-2024 | Ocrevus, Enspryng |
| Alexion Pharmaceuticals, INC. | $355.47 | 2021-2024 | Ultomiris |
| Abbvie INC. | $297.71 | 2021-2024 | |
| Acadia Pharmaceuticals INC | $267.43 | 2019-2023 | Nuplazid |
| Banner Life Sciences, LLC | $254.55 | 2021-2024 | |
| Lundbeck LLC | $232.90 | 2021-2024 | Vyepti |
| Argenx US, INC. | $229.53 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Celgene Corporation | $218.48 | 2023-2024 | Zeposia |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.